Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct‐acting antiviral therapy including first‐ and second‐generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin-Reference-Cited by-同舟云学术

Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct‐acting antiviral therapy including first‐ and second‐generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin

Published:2020-05 Issue:5 Volume:27 Page:548-551
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Fedorchenko Sergii V.¹^ORCID,Martynovych Tatiana¹^ORCID,Klimenko Zhanna¹^ORCID,Yanchenko Vitaliy¹^ORCID,Solianyk Iryna¹

Affiliation:

1. Department of Viral Hepatitis and AIDS The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease Kiev Ukraine

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13254

Reference8 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study;Black S;Lancet,2017

2. FedorchenkoSV.Hronicheskaya HCV‐infekcia [Chronic HCV‐infection.] (Monograph). Kiev: VSI “Medicina”;2010. 270p.

3. Effectiveness, safety and clinical outcomes of direct‐acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real‐world cohort;Crespo J;J Hepatol,2017

4. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

5. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HCV resistance-associated substitutions following direct-acting antiviral therapy failure – Real-life data from Poland;Infection, Genetics and Evolution;2021-09

2. Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries;Clinical Infectious Diseases;2021-07-03

3. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors;Journal of Medical Virology;2021-03-25

4. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life;Antiviral Therapy;2020